AR006188A1 - "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". - Google Patents

"composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".

Info

Publication number
AR006188A1
AR006188A1 ARP970100967A ARP970100967A AR006188A1 AR 006188 A1 AR006188 A1 AR 006188A1 AR P970100967 A ARP970100967 A AR P970100967A AR P970100967 A ARP970100967 A AR P970100967A AR 006188 A1 AR006188 A1 AR 006188A1
Authority
AR
Argentina
Prior art keywords
serinprotease
inhibit
activity
composition
prepare
Prior art date
Application number
ARP970100967A
Other languages
English (en)
Original Assignee
Aerovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovance Inc filed Critical Aerovance Inc
Publication of AR006188A1 publication Critical patent/AR006188A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)

Abstract

Presenta proteinas, polipéptidos, secuencias de ácido nucleico, construcciones, vectores de expresión, células huesped, composicionesfarmacéuticas de bicunina placentaria humana, dominios de inhibición de la serina proteasa, yfragme ntos de los mismos, y métodos para usarlos.
ARP970100967A 1996-03-11 1997-03-11 "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". AR006188A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04

Publications (1)

Publication Number Publication Date
AR006188A1 true AR006188A1 (es) 1999-08-11

Family

ID=27359773

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP970100967A AR006188A1 (es) 1996-03-11 1997-03-11 "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
ARP060101562A AR053063A2 (es) 1996-03-11 2006-04-20 Proteina sustancialmente purificada y composicion farmaceutica que la comprende
ARP070100116A AR058982A1 (es) 1996-03-11 2007-01-11 Vector de expresion de la proteina bicunina y metodo para producir dicha proteina

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP060101562A AR053063A2 (es) 1996-03-11 2006-04-20 Proteina sustancialmente purificada y composicion farmaceutica que la comprende
ARP070100116A AR058982A1 (es) 1996-03-11 2007-01-11 Vector de expresion de la proteina bicunina y metodo para producir dicha proteina

Country Status (27)

Country Link
US (3) US6583108B1 (es)
EP (1) EP0891426B1 (es)
JP (2) JP3469584B2 (es)
KR (1) KR100356956B1 (es)
AR (3) AR006188A1 (es)
AT (1) ATE328083T1 (es)
AU (1) AU716923B2 (es)
BR (1) BR9708021A (es)
CA (1) CA2247888A1 (es)
CO (1) CO4600683A1 (es)
DE (1) DE69735996T2 (es)
DK (1) DK0891426T3 (es)
ES (1) ES2263174T3 (es)
HR (1) HRP970144B1 (es)
HU (1) HU226419B1 (es)
ID (1) ID16224A (es)
IL (1) IL126115A (es)
IN (1) IN192874B (es)
MY (1) MY120693A (es)
NZ (1) NZ331540A (es)
PA (1) PA8426301A1 (es)
PL (1) PL188387B1 (es)
PT (1) PT891426E (es)
SV (1) SV1997000018A (es)
TR (1) TR199801794T2 (es)
WO (1) WO1997033996A2 (es)
YU (1) YU8997A (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69632435T2 (de) * 1995-07-24 2005-05-12 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
HU226419B1 (en) 1996-03-11 2008-12-29 Aerovance Human bikunin
CA2279345A1 (en) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
CA2356404C (en) * 1998-12-22 2010-03-30 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
CA2460653A1 (en) * 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
CA2536918A1 (en) 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
US7566567B2 (en) * 2003-10-10 2009-07-28 Multicell Technologies Inc. Immortalized hepatocytes
EP1675874A1 (en) * 2003-10-16 2006-07-05 Bayer HealthCare LLC Monoclonal antibodies for detection of urinary trypsin inhibitors
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
US20060010098A1 (en) 2004-06-04 2006-01-12 Goodnow Timothy T Diabetes care host-client architecture and data management system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
PL2360258T3 (pl) 2005-02-18 2015-03-31 Angiochem Inc Polipeptydy aprotyniny do transportowania związków przez barierę krew-mózg
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
EP2433653B1 (en) 2005-07-15 2019-06-05 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
EP2074138A4 (en) * 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
US20100063146A1 (en) * 2006-11-07 2010-03-11 Medof M Edward Method for treating disorders related to complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
BRPI0910557A2 (pt) * 2008-04-18 2015-09-29 Angiochem Inc composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
JP2012524030A (ja) 2009-04-20 2012-10-11 アンジオケム インコーポレーテッド Ａｎｇｉｏｐｅｐ−２アナログにコンジュゲート化した抗癌剤を用いた卵巣癌の治療
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
JP6037841B2 (ja) 2010-01-06 2016-12-07 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
CA2839917A1 (en) 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
JP2015504675A (ja) 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
AU2013302270A1 (en) 2012-08-14 2015-03-26 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
CN110092837B (zh) 2014-02-24 2024-01-02 武田有限公司 Uti融合蛋白
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
CA3174478A1 (en) 2020-03-05 2021-09-10 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0401508B1 (de) * 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
EP0439442B1 (en) 1990-01-25 1996-03-06 Washington University Factor x-laci hybrid protein
DE573603T1 (de) 1991-03-01 1999-05-06 Dyax Corp., Cambridge, Mass. Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g.
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
US5747449A (en) 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
EP0740702A1 (en) 1992-12-02 1996-11-06 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
ATE275583T1 (de) 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (fr) 1994-07-21 1996-02-08 The Green Cross Corporation Procede de production d'un inhibiteur de la trypsine urinaire et des domaines de celui-ci, nouveau polypeptide associe et procede de production de ce polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
CA2220497A1 (en) 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
DE69632435T2 (de) * 1995-07-24 2005-05-12 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
HU226419B1 (en) 1996-03-11 2008-12-29 Aerovance Human bikunin
CA2279345A1 (en) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
US7019123B2 (en) 2006-03-28
AR053063A2 (es) 2007-04-18
YU8997A (sh) 1999-09-27
SV1997000018A (es) 1999-01-14
DE69735996D1 (de) 2006-07-06
IN192874B (es) 2004-05-29
CA2247888A1 (en) 1997-09-18
CO4600683A1 (es) 1998-05-08
MY120693A (en) 2005-11-30
AR058982A1 (es) 2008-03-05
HUP9902698A2 (hu) 1999-11-29
JP3469584B2 (ja) 2003-11-25
PL188387B1 (pl) 2005-01-31
WO1997033996A2 (en) 1997-09-18
EP0891426A2 (en) 1999-01-20
US7452859B2 (en) 2008-11-18
DK0891426T3 (da) 2006-10-02
PL328822A1 (en) 1999-02-15
HU226419B1 (en) 2008-12-29
PT891426E (pt) 2006-10-31
AU2207797A (en) 1997-10-01
ATE328083T1 (de) 2006-06-15
NZ331540A (en) 1999-10-28
KR19990087697A (ko) 1999-12-27
ES2263174T3 (es) 2006-12-01
EP0891426B1 (en) 2006-05-31
US6583108B1 (en) 2003-06-24
IL126115A (en) 2007-03-08
IL126115A0 (en) 1999-05-09
PA8426301A1 (es) 2000-05-24
US20030194398A1 (en) 2003-10-16
HUP9902698A3 (en) 2001-06-28
BR9708021A (pt) 1999-07-27
TR199801794T2 (xx) 2000-07-21
JP2001521367A (ja) 2001-11-06
JP2004000208A (ja) 2004-01-08
HRP970144A2 (en) 1998-04-30
DE69735996T2 (de) 2007-02-15
AU716923B2 (en) 2000-03-09
KR100356956B1 (ko) 2003-03-15
ID16224A (id) 1997-09-11
WO1997033996A3 (en) 1997-11-13
US20060172946A1 (en) 2006-08-03
HRP970144B1 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE60144145D1 (de) Subtilisin-variante
AR008727A1 (es) COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO
DK0506884T3 (da) Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
BR0013542A (pt) Moléculas b7-4 e usos para as mesmas
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
NO960309L (no) Agonister og antagonister for humaninterleukin-10
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
NO984491L (no) SCF-analogpreparater og fremgangsmÕte for fremstilling av disse
BR9507473A (pt) Sequéncia de dna isolada vetor célula hospedeira processo para produzir uma proteina gp350 homogénea proteína gp350 homogénea composição farmacéutica e uso na proteina gp350 homogénea
DE69734596D1 (de) "smoothened" proteine aus wirbeltieren
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
ES2196864T3 (es) Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1.
ECSP972054A (es) Bicunina humana
ATE362531T1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
FG Grant, registration